Medicine and Dentistry
Acute Myeloid Leukemia
66%
Overall Survival
52%
Malignant Neoplasm
40%
Cohort Analysis
40%
Case-Control Study
40%
Diffuse Large B-Cell Lymphoma
34%
Diabetes Mellitus
33%
Sodium Nitroprusside
33%
Hepatitis D
33%
Human Immunodeficiency Virus
33%
Venetoclax
33%
NPM1
33%
Transplantation
33%
Leukemia
33%
Hepatitis Delta Virus
33%
Myeloproliferative Neoplasm
33%
Glycon
33%
Somatics
33%
Socioeconomic Status
33%
Immigrant
33%
B-Cell Lymphoma
33%
Hypomethylating Agent
33%
Loss of Function Mutation
33%
Hazard Ratio
29%
Multiple Myeloma
28%
Artery
26%
Type 1 Diabetes
20%
Disease
15%
Odds Ratio
14%
Nitric Oxide
13%
Placenta
13%
Single Drug Dose
13%
Clinical Trial
11%
Prevalence
9%
Proportional Hazards Model
6%
Placental Insufficiency
6%
Nitric Oxide Donor
6%
Pre-Eclampsia
6%
Smooth Muscle Cell
6%
Concentration Response
6%
Vaginal Delivery
6%
Blood Vessel Tone
6%
Cesarean Section
6%
Hemodynamic
6%
Insulin Dependent Diabetes Mellitus
6%
Muscle Contractility
6%
Isometrics
6%
Prostaglandin F2
6%
Trophoblast
6%
Spiral Artery
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Overall Survival
77%
Venetoclax
66%
Case-Control Study
66%
Myeloproliferative Neoplasm
66%
Malignant Neoplasm
56%
Chemotherapy
48%
Remission
44%
Cohort Study
40%
Disease
38%
Leukemia
37%
Delta Agent Hepatitis
33%
Obesity
33%
HIV
33%
Hepatitis Delta Virus
33%
Metformin
33%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
33%
Multiple Myeloma
28%
Diffuse Large B Cell Lymphoma
28%
Statin (Protein)
20%
Recurrence Free Survival
16%
Cytarabine
11%
Azacitidine
11%
Minimal Residual Disease
11%
Survival Time
11%
Event Free Survival
11%
Prevalence
9%
Population Study
7%
Liver Cell Carcinoma
5%
Mixed Infection
5%
Virus Infection
5%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Case-Control Study
66%
Cohort Study
38%
Myeloid
36%
B Cell
34%
NPM1
33%
Statin
33%
Population Research
20%
Dose Response
16%
Population
16%
Event Free Survival
16%
Cytarabine
16%
Quantitative Reverse Transcription Polymerase Chain Reaction
16%
Low Drug Dose
16%
Azacitidine
16%
Recurrence Free Survival
16%
Philadelphia Chromosome
11%
T Cell
5%
Cytogenetics
5%
High Risk Population
5%
